Moderna Reports Sharp Decline in COVID-19 Vaccine Sales, Outperforms Expectations

Despite a 91% drop in sales, Moderna's first-quarter earnings exceeded Wall Street forecasts, with a smaller-than-anticipated loss and a promising outlook for new vaccines.